application with the FDA for marketing approval of Acapodene for
may not result in marketing approval from the FDA.1Table of ContentsAcapodene for the Treatment of Side Effects
Phase II clinical trial evaluated the use of Acapodene
Phase II clinical trial evaluated Acapodene in patients who
for the treatment of muscle wasting weight loss from cancer.We have completed three Phase I clinical
molecule drugs that modulate the effects of hormones.Early Stage CompanyAll of our product candidates are undergoing
respective owners.3Table of ContentsThe OfferingCommon stock offered by GTx5,400,000 sharesCommon stock to be outstanding after the offering24,592,753 sharesNasdaq National Market symbolGTXIUse of proceedsWe expect to use the net proceeds from this
development activities and for general corporate purposes.The number of shares of common stock to be
its effect would be antidilutive.Nine Months EndedYear Ended December 31,September 30,20002001200220022003(unaudited)(in thousands, except share and per share data)Statement of Operations Data:Operating expenses:Research and development$2,679$5,744$9,285$6,408$7,123General and administrative1,2032,1872,4051,8302,339Depreciation80215332240264Total operating expenses3,9628,14612,0228,4789,726Interest income1508315610579Net loss(3,812)(8,063)(11,866)(8,373)(9,647)Accrued preferred stock dividends(297)(790)(2,147)(1,466)(2,300)Adjustment to preferred stock redemption value(21,077)(57)(7,220)(7,147)(76,666)Net loss attributable to common stockholders$(25,186)$(8,910)$(21,233)$(16,986)$(88,613)Net loss per share attributable to common
commissions and estimated offering expenses payable by us.As of September 30, 2003ActualAs Adjusted(in thousands)Balance Sheet Data:Cash and cash equivalents$19,788$87,796Working capital18,28086,289Total assets21,10789,115Cumulative redeemable convertible preferred stock162,978—Deficit accumulated during development stage(144,891)(145,159)Total stockholders’ (deficit) equity(143,838)87,1496Table of ContentsRISK FACTORSRisks Related to Our Financial Results and
programs or commercialization efforts.We will need to raise additional capital to:•fund our operations and clinical trials;•continue our research and development; and•commercialize our product candidates, if any such
product candidates receive regulatory approval for commercial
including noncompliance with regulatory requirements; and•the effects of our product candidates may not be
cost, clinical development and commercialization of our product
our ability to develop product candidates and commercialize any
development and commercialization of these product candidates.Use of third-party manufacturers may
develop our product candidates and compete effectively.
conduct clinical trials for our product candidates, and we must
regulatory approval to market any of our product candidates in
FDA for marketing approval of a product candidate, it may not
commercial sale, will depend on a number of factors, including:•the prevalence and severity of any side effects;•potential advantages over alternative treatments;•the ability to offer our product candidates for
sale of commercial products if marketing approval is obtained
develop and market products that are more effective than any
clinical trials, obtaining regulatory approvals and marketing
significant impact on the market price of our common stock:•adverse results or delays in our clinical trials;•the timing of achievement of our clinical,
to our product candidates, our clinical trials or our sales and
marketing activities;•the commercial success of any product approved by
issued and outstanding, as adjusted824Deferred stock compensation(3,408)(3,408)Additional paid-in capital4,453235,692Deficit accumulated during the development stage(144,891)(145,159)Total stockholders’ (deficit) equity(143,838)87,149Total capitalization$19,140$87,14923Table of ContentsDILUTIONOur net tangible book value as of
its effect would be antidilutive.Nine Months EndedYear Ended December 31,September 30,1998199920002001200220022003(unaudited)(in thousands, except share and per share data)Statement of Operations Data:Operating expenses:Research and development$185$518$2,679$5,744$9,285$6,408$7,123General and administrative1792561,2032,1872,4051,8302,339Depreciation194580215332240264Total operating expenses3838193,9628,14612,0228,4789,726Other income:Research and development income225——————Interest income42691508315610579Total other income267691508315610579Net loss(116)(750)(3,812)(8,063)(11,866)(8,373)(9,647)Accrued preferred stock dividends—(83)(297)(790)(2,147)(1,466)(2,300)Adjustment to preferred stock redemption value——(21,077)(57)(7,220)(7,147)(76,666)Net loss attributable to common stockholders$(116)$(833)$(25,186)$(8,910)$(21,233)$(16,986)$(88,613)Net loss per share attributable to common
prostate cancer in men with high grade PIN, including our Phase
IIb clinical trial; Acapodene for the treatment of side effects
forms of cancer, including three Phase I clinical trials; and
candidates included in the table above.Drug development in the United States is a
clinical trials, a New Drug application, or NDA, may be
clinical trials and general market conditions.Comparison of Years Ended December 31,
Research and development expenses on other product candidates
clinical trials and other research and development activities;•future clinical trial results;•the terms and timing of any collaborative,
clinical trials and other research and development activities;•future clinical trial results;•the terms and timing of any collaborative,
clinical trials and other research and development activities;•future clinical trial results;•the terms and timing of any collaborative,
modulate the effects of hormones.Our most advanced product candidate is Acapodene,
prostate cancer in men with high grade PINPhase IIb clinical trialEnrollment complete; last patient scheduled to
prostate cancer in men with high grade PINPhase IIb clinical trialEnrollment complete; last patient scheduled to
clinical trial of Acapodene in 21 patients with high grade PIN.
adverse events attributable to Acapodene in this trial.Based on the results from our Phase IIa clinical